

Special Issue

Clinical and Methodological Aspects of HSC Transplantation in Hematological Malignancies

Message from the Guest Editor

Since the mid-20th century, hematopoietic stem cell transplantation (HSCT) has been used to treat defective or leukemic hematopoiesis in congenital and acquired diseases. Since its first use, HSCT had developed and improved considerably, and today, it represents a unique opportunity to cure several hematological malignancies. Thanks to the current knowledge of immunogenetics, stem cell biology, the antineoplastic and immunosuppressive properties of several drugs, and ex vivo procedures, HSCT can be applied to treat patients within a wide age range, and can overcome HLA- and ABO-group barriers. The ability of HSCT to manage the main adverse immune effects (i.e., graft versus host disease), and to maintain its intended immune effects (i.e., graft versus malignancy), renders it a powerful therapeutic strategy for preventing disease relapse or progression, and an instructive model for the development of future cell therapies.

Guest Editor

Prof. Dr. Luca Pierelli

1. Immunohematology and Transfusion Medicine, San Camillo-Forlanini Hospital, 00152 Rome, Italy

2. Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy

Deadline for manuscript submissions

closed (31 January 2024)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/172422

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/

[cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).